CA-DIALPAD-INC.
13.7.2021 12:12:10 CEST | Business Wire | Press release
Dialpad Inc. , the industry leader in AI-powered communication and collaboration, today announced a truly unified approach to communications as a service. With the launch of Dialpad Meetings , the company is bringing its suite of products closer together across both business communications and customer engagement all on one unified, aesthetically cohesive platform with AI at its core.
Dialpad Meetings, formerly known as UberConference, adds new capabilities and establishes the Dialpad cloud communications platform as the one place for a truly unified Communications as a Service (TruCaaS) experience. With a TruCaaS solution delivered through a single pane of glass with an intuitive interface, Dialpad helps customers simplify business collaboration and avoid the growing phenomenon of “app overload.”
“At Dialpad, we believe when the right people come together anything is possible, and we want our brand to reflect this spirit of connection, collaboration and productivity in this new work-from-anywhere world,” said Craig Walker, CEO of Dialpad. “With today’s announcements, we are resetting expectations for communication experiences by building a business communication platform that is more beautiful, accessible, easy to deploy and easy to use — to help businesses of any size start, grow and scale.”
To bring the vision of TruCaaS to life, Dialpad is making the following capabilities available in its single, powerful platform:
-
Dialpad Meetings
- The reliable UberConference technology customers know and love with a new look and set of features, including:
- Video conferencing in HD quality for an in-the-room experience
- Real-time Voice Intelligence (Vi™) provides live note-taking and automated transcription analysis, enabling attendees to focus on the conversation and ensure key moments are not missed.
- Start and join Dialpad Meetings from any direct message, group message or channel within the Dialpad app. With Dialpad Meetings natively built into the platform, users are not required to manage multiple tabs or windows.
- Emoji reactions and expressions build social connections with team members and provide feedback in real-time without interruptions.
- Dialpad Channels - With one click, Dialpad Channels offers teams a “light lift” collaboration tool for quick text and/or audio conversations. By providing a space for informal chats, office hours and other water cooler conversations, Dialpad Channels combats video conferencing fatigue and reduces the need for formal 30-minute meetings.
- Mobile screen sharing - Dialpad users can now share their screens on phone calls, whether everyone is a Dialpad user or not. No need to set an official meeting or jump onto a conference call to quickly resolve issues, collaborate on projects or do virtual walkthroughs.
- Global availability - Dialpad Meetings is available through the Dialpad platform with connectivity in 49 countries.
After winning TechCrunch Disrupt NYC in 2012 for UberConference and igniting the work-from-anywhere movement, Dialpad is disrupting an industry built on legacy thinking. As part of this vision and aligned with its TruCaaS approach, Dialpad is launching its Work Beautifully campaign to further support and enable the hybrid workplace.
“Work Beautifully is the big-picture concept that the Dialpad brand and products aspire to. Not only do our talk, messaging, meetings and contact center products work beautifully, they enable others to work beautifully and collaboratively together,” said Morgan Norman, Chief Marketing Officer, Dialpad. “This bold, new visual identity honors Dialpad’s ground-breaking story, its history of innovation in communications, and is deeply rooted in the company’s core values: do the right thing, every voice matters, and experience first.”
The future of work is not restrained by employee or customer location, but is instead borderless; enabled by AI across every experience and seamlessly integrated into how people collaborate and create. Companies that embrace work-from-anywhere technology and empower employee and customer experiences with AI have a significant advantage over those that hold tight to outdated modes of communication, collaboration and productivity. Dialpad’s new release with integrated talk, messaging, meetings and contact center — all powered by AI across every experience — arrives at the right moment to help businesses thrive in this post-pandemic, work-from-anywhere world.
“Work Beautifully means simplicity and ease. Dialpad even takes notes and transcribes calls for us. It’s that flow state where work doesn’t feel like work anymore,” said Chad Pierce, Head of Building Technology, WeWork. “Dialpad makes it easy for our teams to stay close, wherever work finds them and frees our teams to collaborate from anywhere on the planet.”
Additional Resources
- Get started with Dialpad today on a 14-day free trial
- Learn more about Dialpad Channels
- Explore the what, how and why of Voice Intelligence in the contact center
- Discover how Dialpad utilizes AI to unify UCaaS and CCaaS
Social Networks:
- Web: https://www.dialpad.com/
- Blog: https://www.dialpad.com/blog/
- Twitter: https://twitter.com/dialpadHQ/
- LinkedIn: https://www.linkedin.com/company/dialpad/
- Facebook: https://www.facebook.com/Dialpadhq/
- Instagram: https://www.instagram.com/Dialpad/
About Dialpad
Dialpad is the leading cloud communications platform for talk, messaging, meetings and contact center in one beautiful app. Dialpad’s platform delivers AI across every employee and customer experience through real-time transcriptions, live agent coaching and sentiment analysis. More than 73,000 of the world’s most innovative businesses, including Domo, Motorola Solutions, Netflix, Splunk, Stripe, T-Mobile, Twitter, Uber and WeWork use Dialpad to connect and collaborate. Dialpad is backed by the world’s leading investors including Amasia, Andreessen Horowitz, Felicis Ventures, GV, ICONIQ Capital, OMERS Growth Equity, Salesforce Ventures, Scale Ventures, Section 32, SoftBank Corp., T-Mobile Ventures and Work-Bench. Visit www.dialpad.com for more information and to request a demo.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005389/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
